Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -117.78% | -85.50% | 31.73% | 28.26% | 27.49% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 283.90% | 199.98% | -26.45% | -7.05% | 8.20% |
| Change in Net Operating Assets | 59.45% | 357.70% | -1,625.89% | -449.08% | -175.08% |
| Cash from Operations | -43.76% | 18.51% | 21.84% | 12.85% | -2.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -377.63% | -390.98% | 200.31% | 166.88% | 183.50% |
| Cash from Investing | -377.63% | -390.98% | 200.31% | 166.88% | 183.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,164.72% | 2,763.59% | 91.61% | 138.39% | 377.47% |
| Repurchase of Common Stock | -450.25% | -121.96% | 30.56% | 46.31% | 46.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,171.36% | 2,824.84% | 90.56% | 140.44% | 415.54% |
| Foreign Exchange rate Adjustments | 127.27% | 102.98% | 92.82% | 95.36% | 43.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,432.37% | 4,289.79% | 105.74% | 88.16% | 117.22% |